在这项研究中，我们研究了稳定的固体分散体的配方，以提高奥拉帕尼（OLA）的生物利用度，奥拉帕尼是一种卵巢癌和乳腺癌的治疗剂，具有低溶解度和低渗透性的BCS IV类药物。根据溶解度测试筛选各种聚合物，并利用喷雾干燥制备负载OLA的固体分散体。通过扫描电子显微镜 (SEM)、差示扫描量热法 (DSC)、粉末 X 射线衍射 (PXRD) 和傅里叶变换红外光谱 (FT-IR) 研究了这些分散体的物理化学性质。随后的溶出测试以及对水溶液形态和结晶度变化的评估，最终选择了基于羟丙甲纤维素 (HPMC) 的 OLA 固体分散体作为最佳配方。 HPMC 可有效维持 OLA 在水溶液中的过饱和度，并表现出稳定的无定形状态，无需重结晶。在体内研究中，这种基于 HPMC 的 OLA 固体分散体显着增强了生物利用度，与 OLA 药粉（结晶 OLA）相比，AUC0-24 提高了 4.19 倍，Cmax 提高了 10.68 倍以上。我们的结果强调了基于 HPMC 的固体分散体在提高 OLA 口服生物利用度方面的有效性，并表明它们可以成为开发口服药物制剂的有效工具。

In this study, we investigated the formulation of stable solid dispersions to enhance the bioavailability of olaparib (OLA), a therapeutic agent for ovarian cancer and breast cancer characterized as a BCS class IV drug with low solubility and low permeability. Various polymers were screened based on solubility tests, and OLA-loaded solid dispersions were prepared using spray drying. The physicochemical properties of these dispersions were investigated via scanning electron microscopy (SEM), differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD), and Fourier Transform Infrared Spectroscopy (FT-IR). Subsequent dissolution tests, along with assessments of morphological and crystallinity changes in aqueous solutions, led to the selection of a hypromellose (HPMC)-based OLA solid dispersion as the optimal formulation. HPMC was effective at maintaining the supersaturation of OLA in aqueous solutions and exhibited a stable amorphous state without recrystallization. In an in vivo study, this HPMC-based OLA solid dispersion significantly enhanced bioavailability, increasing AUC0-24 by 4.19-fold and Cmax by more than 10.68-fold compared to OLA drug powder (crystalline OLA). Our results highlight the effectiveness of HPMC-based solid dispersions in enhancing the oral bioavailability of OLA and suggest that they could be an effective tool for the development of oral drug formulations.